Karine Rp Breckpot

List of Publications by Year in Descending Order

137 papers	6,157 citations	46 h-index	74 g-index
147 ext. papers	7,277 ext. citations	6.8 avg, IF	5.62 L-index

#	Paper	IF	Citations
137	Assessing Tumor-Infiltrating Lymphocytes in Breast Cancer: A Proposal for Combining Immunohistochemistry and Gene Expression Analysis to Refine Scoring.. *Frontiers in Immunology*, **2022**, 13, 794175	8.4	0
136	The antigen-binding moiety in the driver's seat of CARs. *Medicinal Research Reviews*, **2022**, 42, 306-342	14.4	3
135	Oncolytic Herpes Simplex Virus Type 1 Induces Immunogenic Cell Death Resulting in Maturation of BDCA-1 Myeloid Dendritic Cells.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	1
134	RNA in cancer immunotherapy: unlocking the potential of the immune system.. *Clinical Cancer Research*, **2022**,	12.9	1
133	Evaluation of single domain antibodies as nuclear tracers for imaging of the immune checkpoint receptor human lymphocyte activation gene-3 in cancer. *EJNMMI Research*, **2021**, 11, 115	3.6	1
132	CS1-specific single-domain antibodies labeled with Actinium-225 prolong survival and increase CD8+ T cells and PD-L1 expression in Multiple Myeloma. *OncoImmunology*, **2021**, 10, 2000699	7.2	0
131	Unraveling the Effects of a Talimogene Laherparepvec (T-VEC)-Induced Tumor Oncolysate on Myeloid Dendritic Cells. *Frontiers in Immunology*, **2021**, 12, 733506	8.4	1
130	Immunogenicity Risk Profile of Nanobodies. *Frontiers in Immunology*, **2021**, 12, 632687	8.4	32
129	mRNA in cancer immunotherapy: beyond a source of antigen. *Molecular Cancer*, **2021**, 20, 48	42.1	16
128	Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential. *Frontiers in Immunology*, **2021**, 12, 652160	8.4	5
127	Single-Domain Antibody Nuclear Imaging Allows Noninvasive Quantification of LAG-3 Expression by Tumor-Infiltrating Leukocytes and Predicts Response of Immune Checkpoint Blockade. *Journal of Nuclear Medicine*, **2021**, 62, 1638-1644	8.9	10
126	Overcoming the Challenges of High Quality RNA Extraction from Core Needle Biopsy. *Biomolecules*, **2021**, 11,	5.9	1
125	Site-Specific Radiolabeling of a Human PD-L1 Nanobody via Maleimide-Cysteine Chemistry. *Pharmaceuticals*, **2021**, 14,	5.2	3
124	Fractionated Radiation Severely Reduces the Number of CD8+ T Cells and Mature Antigen Presenting Cells Within Lung Tumors. *International Journal of Radiation Oncology Biology Physics*, **2021**, 111, 272-283	4	6
123	Formatting and gene-based delivery of a human PD-L1 single domain antibody for immune checkpoint blockade. *Molecular Therapy - Methods and Clinical Development*, **2021**, 22, 172-182	6.4	2
122	Neo-Antigen mRNA Vaccines. *Vaccines*, **2020**, 8,	5.3	24
121	Preclinical Targeted □and □Radionuclide Therapy in HER2-Positive Brain Metastasis Using Camelid Single-Domain Antibodies. *Cancers*, **2020**, 12,	6.6	21

120	The Next-Generation Immune Checkpoint LAG-3 and Its Therapeutic Potential in Oncology: Third Time's a Charm. *International Journal of Molecular Sciences*, **2020**, 22,	6.3	24
119	Anti-human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation. *Biomolecules*, **2020**, 10,	5.9	15
118	Hepatocarcinoma Induces a Tumor Necrosis Factor-Dependent Kupffer Cell Death Pathway That Favors Its Proliferation Upon Partial Hepatectomy. *Frontiers in Oncology*, **2020**, 10, 547013	5.3	4
117	Targeting Neuropilin-1 with Nanobodies Reduces Colorectal Carcinoma Development. *Cancers*, **2020**, 12,	6.6	11
116	Noninvasive Imaging of the Immune Checkpoint LAG-3 Using Nanobodies, from Development to Pre-Clinical Use. *Biomolecules*, **2019**, 9,	5.9	29
115	Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells. *Cancers*, **2019**, 11,	6.6	11
114	Single-domain antibody fusion proteins can target and shuttle functional proteins into macrophage mannose receptor expressing macrophages. *Journal of Controlled Release*, **2019**, 299, 107-120	11.7	11
113	Broadening the Message: A Nanovaccine Co-loaded with Messenger RNA and αGalCer Induces Antitumor Immunity through Conventional and Natural Killer T Cells. *ACS Nano*, **2019**, 13, 1655-1669	16.7	21
112	Single Domain Antibody-Mediated Blockade of Programmed Death-Ligand 1 on Dendritic Cells Enhances CD8 T-cell Activation and Cytokine Production. *Vaccines*, **2019**, 7,	5.3	11
111	Commentary: Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. *Frontiers in Cell and Developmental Biology*, **2019**, 7, 149	5.7	5
110	Evaluating a Single Domain Antibody Targeting Human PD-L1 as a Nuclear Imaging and Therapeutic Agent. *Cancers*, **2019**, 11,	6.6	31
109	Theranostics in immuno-oncology using nanobody derivatives. *Theranostics*, **2019**, 9, 7772-7791	12.1	48
108	Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression. *Cancer Research*, **2018**, 78, 1155-1168	10.1	19
107	Noninvasive imaging of the PD-1:PD-L1 immune checkpoint: Embracing nuclear medicine for the benefit of personalized immunotherapy. *Theranostics*, **2018**, 8, 3559-3570	12.1	59
106	Towards a personalized iPSC-based vaccine. *Nature Biomedical Engineering*, **2018**, 2, 277-278	19	2
105	Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects. *OncoImmunology*, **2018**, 7, e1484981	7.2	17
104	A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. *Oncotarget*, **2018**, 9, 27797-27808	3.3	14
103	The Journey of Virus Engineered Dendritic Cells From Bench to Bedside: A Bumpy Road. *Frontiers in Immunology*, **2018**, 9, 2052	8.4	10

102	Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression. *Frontiers in Immunology*, **2018**, 9, 1977	8.4	78
101	Dendritic Cell Targeting mRNA Lipopolyplexes Combine Strong Antitumor T-Cell Immunity with Improved Inflammatory Safety. *ACS Nano*, **2018**, 12, 9815-9829	16.7	46
100	Adult-Derived Human Liver Stem/Progenitor Cells Infused 3 Days Postsurgery Improve Liver Regeneration in a Mouse Model of Extended Hepatectomy. *Cell Transplantation*, **2017**, 26, 351-364	4	6
99	Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery. *Gene Therapy*, **2017**, 24, 370-375	4	7
98	Adjuvant-Enhanced mRNA Vaccines. *Methods in Molecular Biology*, **2017**, 1499, 179-191	1.4	5
97	Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation. *Journal of Pathology*, **2017**, 241, 534-546	9.4	32
96	Co-delivery of nucleoside-modified mRNA and TLR agonists for cancer immunotherapy: Restoring the immunogenicity of immunosilent mRNA. *Journal of Controlled Release*, **2017**, 266, 287-300	11.7	70
95	PD1 signal transduction pathways in T cells. *Oncotarget*, **2017**, 8, 51936-51945	3.3	118
94	Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers. *Oncotarget*, **2017**, 8, 41932-41946	3.3	69
93	PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity. *Cell Reports*, **2017**, 20, 1818-1829	10.6	128
92	Intralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumours. *Scientific Reports*, **2016**, 6, 22509	4.9	39
91	Particle-mediated Intravenous Delivery of Antigen mRNA Results in Strong Antigen-specific T-cell Responses Despite the Induction of Type I Interferon. *Molecular Therapy - Nucleic Acids*, **2016**, 5, e326	10.7	50
90	Intratumoral Delivery of TriMix mRNA Results in T-cell Activation by Cross-Presenting Dendritic Cells. *Cancer Immunology Research*, **2016**, 4, 146-56	12.5	61
89	Myeloid-Derived Suppressor Cells and Cancer. *SpringerBriefs in Immunology*, **2016**,		2
88	Myeloid-derived suppressor cells reveal radioprotective properties through arginase-induced l-arginine depletion. *Radiotherapy and Oncology*, **2016**, 119, 291-9	5.3	14
87	Hitchhiking nanoparticles: Reversible coupling of lipid-based nanoparticles to cytotoxic T lymphocytes. *Biomaterials*, **2016**, 77, 243-54	15.6	53
86	RAS Association Domain Family Member 4 (RASSF4): A New Potent Tumor Suppressor in Multiple Myeloma. *Blood*, **2016**, 128, 2057-2057	2.2	1
85	Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy. *Oncotarget*, **2016**, 7, 42698-42715	3.3	27

84	Signal Transducer and Activation of Transcription 3: A Master Regulator of Myeloid-Derived Suppressor Cells. *SpringerBriefs in Immunology*, **2016**, 73-90		
83	Cancer-Associated Myeloid Regulatory Cells. *Frontiers in Immunology*, **2016**, 7, 113	8.4	49
82	Phosphorylated STAT5 regulates p53 expression via BRCA1/BARD1-NPM1 and MDM2. *Cell Death and Disease*, **2016**, 7, e2560	9.8	13
81	Intratumoral delivery of mRNA: Overcoming obstacles for effective immunotherapy. *OncoImmunology*, **2015**, 4, e1005504	7.2	10
80	Phosphorylated STAT3 physically interacts with NPM and transcriptionally enhances its expression in cancer. *Oncogene*, **2015**, 34, 1650-7	9.2	5
79	The ReNAissanCe of mRNA-based cancer therapy. *Expert Review of Vaccines*, **2015**, 14, 235-51	5.2	47
78	mRNA-based dendritic cell vaccines. *Expert Review of Vaccines*, **2015**, 14, 161-76	5.2	83
77	Contribution of Cardiac Sodium Channel β-Subunit Variants to Brugada Syndrome. *Circulation Journal*, **2015**, 79, 2118-29	2.9	7
76	The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome. *European Journal of Immunology*, **2015**, 45, 3351-61	6.1	11
75	Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer. *Oncotarget*, **2015**, 6, 12369-82	3.3	46
74	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. *Frontiers in Immunology*, **2015**, 6, 588	8.4	239
73	Pros and Cons of Antigen-Presenting Cell Targeted Tumor Vaccines. *Journal of Immunology Research*, **2015**, 2015, 785634	4.5	25
72	Combinatorial strategies for the induction of immunogenic cell death. *Frontiers in Immunology*, **2015**, 6, 187	8.4	228
71	Targeting the tumor microenvironment to enhance antitumor immune responses. *Oncotarget*, **2015** , 6, 1359-81	3.3	53
70	Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells. *Gene Therapy*, **2014**, 21, 262-71	4	62
69	The potential of antigen and TriMix sonoporation using mRNA-loaded microbubbles for ultrasound-triggered cancer immunotherapy. *Journal of Controlled Release*, **2014**, 194, 28-36	11.7	73
68	Choose your models wisely: how different murine bone marrow-derived dendritic cell protocols influence the success of nanoparticulate vaccines in vitro. *Journal of Controlled Release*, **2014**, 195, 138-46	11.7	10
67	Optimized dendritic cell-based immunotherapy for melanoma: the TriMix-formula. *Cancer Immunology, Immunotherapy*, **2014**, 63, 959-67	7.4	60

66	A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice. *Oncotarget*, **2014**, 5, 7843-57	3.3	51
65	Manipulating Immune Regulatory Pathways to Enhance T Cell Stimulation **2014**,		3
64	Consensus guidelines for the detection of immunogenic cell death. *OncoImmunology*, **2014**, 3, e955691	7.2	524
63	Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL. *Molecular Human Reproduction*, **2014**, 20, 168-77	4.4	66
62	Nanoparticle design to induce tumor immunity and challenge the suppressive tumor microenvironment. *Nano Today*, **2014**, 9, 743-758	17.9	49
61	Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using myeloid-derived suppressor cells as a readout of therapeutic efficacy. *OncoImmunology*, **2014**, 3, e945378	7.2	27
60	A personalized view on cancer immunotherapy. *Cancer Letters*, **2014**, 352, 113-25	9.9	45
59	Immunogenicity of targeted lentivectors. *Oncotarget*, **2014**, 5, 704-15	3.3	23
58	Intratumoral administration of mRNA encoding a fusokine consisting of IFN-▯and the ectodomain of the TGF-▯receptor II potentiates antitumor immunity. *Oncotarget*, **2014**, 5, 10100-13	3.3	53
57	Immune modulation by genetic modification of dendritic cells with lentiviral vectors. *Virus Research*, **2013**, 176, 1-15	6.4	17
56	Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70. *Journal of Immunology*, **2013**, 191, 1976-83	5.3	38
55	Downregulation of Stat3 in melanoma: reprogramming the immune microenvironment as an anticancer therapeutic strategy. *Gene Therapy*, **2013**, 20, 1085-92	4	31
54	Targeting of human antigen-presenting cell subsets. *Journal of Virology*, **2013**, 87, 11304-8	6.6	28
53	Design of an Optimized WilmsRTumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo. *Molecular Therapy - Nucleic Acids*, **2013**, 2, e134	10.7	30
52	Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?. *OncoImmunology*, **2013**, 2, e26148	7.2	25
51	mRNA: From a chemical blueprint for protein production to an off-the-shelf therapeutic. *Human Vaccines and Immunotherapeutics*, **2013**, 9, 265-74	4.4	41
50	Role of non-classical MHC class I molecules in cancer immunosuppression. *OncoImmunology*, **2013**, 2, e26491	7.2	94
49	Targeted Lentiviral Vectors: Current Applications and Future Potential **2013**,		2

48	Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model. *PLoS ONE*, **2013**, 8, e65075	3.7	22
47	Lentiviral vectors: a versatile tool to fight cancer. *Current Molecular Medicine*, **2013**, 13, 602-25	2.5	25
46	Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy. *Cancer Research*, **2012**, 72, 1342-52	10.1	28
45	Lentiviral Vectors and Gene Therapy. *SpringerBriefs in Biochemistry and Molecular Biology*, **2012**,		3
44	Preclinical evaluation of TriMix and antigen mRNA-based antitumor therapy. *Cancer Research*, **2012**, 72, 1661-71	10.1	129
43	Retroviral and lentiviral vectors for the induction of immunological tolerance. *Scientifica*, **2012**, 2012,	2.6	16
42	Selective activation of intracellular signalling pathways in dendritic cells for cancer immunotherapy. *Anti-Cancer Agents in Medicinal Chemistry*, **2012**, 12, 29-39	2.2	17
41	The role of SMAC mimetics in regulation of tumor cell death and immunity. *OncoImmunology*, **2012**, 1, 965-967	7.2	8
40	Development of the Nanobody display technology to target lentiviral vectors to antigen-presenting cells. *Gene Therapy*, **2012**, 19, 1133-40	4	49
39	Nanobody-based targeting of the macrophage mannose receptor for effective in vivo imaging of tumor-associated macrophages. *Cancer Research*, **2012**, 72, 4165-77	10.1	221
38	Inhibition of firefly luciferase by general anesthetics: effect on in vitro and in vivo bioluminescence imaging. *PLoS ONE*, **2012**, 7, e30061	3.7	36
37	MODULATING CO-STIMULATION DURING ANTIGEN PRESENTATION TO ENHANCE CANCER IMMUNOTHERAPY. *Immunology, Endocrine and Metabolic Agents in Medicinal Chemistry*, **2012**, 12, 224-235		36
36	PD-L1/PD-1 Co-Stimulation, a Brake for T cell Activation and a T cell Differentiation Signal. *Journal of Clinical & Cellular Immunology*, **2012**, S12,	2.7	21
35	Immunomodulation by Genetic Modification Using Lentiviral Vectors. *SpringerBriefs in Biochemistry and Molecular Biology*, **2012**, 51-67		
34	Clinical Grade Lentiviral Vectors. *SpringerBriefs in Biochemistry and Molecular Biology*, **2012**, 69-85		
33	Development of Retroviral and Lentiviral Vectors. *SpringerBriefs in Biochemistry and Molecular Biology*, **2012**, 11-28		
32	Cell and Tissue Gene Targeting with Lentiviral Vectors. *SpringerBriefs in Biochemistry and Molecular Biology*, **2012**, 29-50		
31	Targeting lentiviral vectors for cancer immunotherapy. *Current Cancer Therapy Reviews*, **2011**, 7, 248-260	0.4	13

30	Selective ERK activation differentiates mouse and human tolerogenic dendritic cells, expands antigen-specific regulatory T cells, and suppresses experimental inflammatory arthritis. *Arthritis and Rheumatism*, **2011**, 63, 84-95		52
29	mRNA: delivering an antitumor message?. *Immunotherapy*, **2011**, 3, 605-7	3.8	14
28	HIV-1 lentiviral vector immunogenicity is mediated by Toll-like receptor 3 (TLR3) and TLR7. *Journal of Virology*, **2010**, 84, 5627-36	6.6	117
27	Primary deficiency of microsomal triglyceride transfer protein in human abetalipoproteinemia is associated with loss of CD1 function. *Journal of Clinical Investigation*, **2010**, 120, 2889-99	15.9	64
26	Lentiviral vectors in gene therapy: their current status and future potential. *Archivum Immunologiae Et Therapiae Experimentalis*, **2010**, 58, 107-19	4	185
25	Variegation and silencing in a lentiviral-based murine transgenic model. *Transgenic Research*, **2010**, 19, 399-414	3.3	18
24	Attenuated expression of A20 markedly increases the efficacy of double-stranded RNA-activated dendritic cells as an anti-cancer vaccine. *Journal of Immunology*, **2009**, 182, 860-70	5.3	60
23	Dendritic cells for active anti-cancer immunotherapy: targeting activation pathways through genetic modification. *Endocrine, Metabolic and Immune Disorders - Drug Targets*, **2009**, 9, 328-43	2.2	46
22	Tissue-targeted therapy of autoimmune diabetes using dendritic cells transduced to express IL-4 in NOD mice. *Clinical Immunology*, **2008**, 127, 176-87	9	60
21	Functional T-cell responses generated by dendritic cells expressing the early HIV-1 proteins Tat, Rev and Nef. *Vaccine*, **2008**, 26, 3735-41	4.1	26
20	Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D: -luciferin: effect on intensity, time kinetics and repeatability of photon emission. *European Journal of Nuclear Medicine and Molecular Imaging*, **2008**, 35, 999-1007	8.8	80
19	Lentiviral vectors for anti-tumor immunotherapy. *Current Gene Therapy*, **2008**, 8, 438-48	4.3	36
18	CD83 expression on dendritic cells and T cells: correlation with effective immune responses. *European Journal of Immunology*, **2007**, 37, 686-95	6.1	148
17	Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics. *Gene Therapy*, **2007**, 14, 847-62	4	91
16	Current approaches in dendritic cell generation and future implications for cancer immunotherapy. *Cancer Immunology, Immunotherapy*, **2007**, 56, 1513-37	7.4	130
15	Expression of human GITRL on myeloid dendritic cells enhances their immunostimulatory function but does not abrogate the suppressive effect of CD4+CD25+ regulatory T cells. *Journal of Leukocyte Biology*, **2007**, 82, 93-105	6.5	46
14	Lentiviruses in cancer immunotherapy. *Future Virology*, **2007**, 2, 597-606	2.4	1
13	Activation of immature monocyte-derived dendritic cells after transduction with high doses of lentiviral vectors. *Human Gene Therapy*, **2007**, 18, 536-46	4.8	40

12	Induction of effective therapeutic antitumor immunity by direct in vivo administration of lentiviral vectors. *Gene Therapy*, **2006**, 13, 630-40	4	88
11	Induction of antigen-specific CD8+ cytotoxic T cells by dendritic cells co-electroporated with a dsRNA analogue and tumor antigen mRNA. *Gene Therapy*, **2006**, 13, 1027-36	4	28
10	Electroporation of immature and mature dendritic cells: implications for dendritic cell-based vaccines. *Gene Therapy*, **2005**, 12, 772-82	4	81
9	Dendritic cells differentiated in the presence of IFN-{beta} and IL-3 are potent inducers of an antigen-specific CD8+ T cell response. *Journal of Leukocyte Biology*, **2005**, 78, 898-908	6.5	22
8	Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses. *Journal of Immunology*, **2004**, 172, 2232-7	5.3	42
7	Activation of monocytes via the CD14 receptor leads to the enhanced lentiviral transduction of immature dendritic cells. *Human Gene Therapy*, **2004**, 15, 562-73	4.8	28
6	Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. *Journal of Immunology*, **2004**, 172, 6649-57	5.3	164
5	Human pancreatic duct cells can produce tumour necrosis factor-alpha that damages neighbouring beta cells and activates dendritic cells. *Diabetologia*, **2004**, 47, 998-1008	10.3	35
4	Exploiting dendritic cells for cancer immunotherapy: genetic modification of dendritic cells. *Journal of Gene Medicine*, **2004**, 6, 1175-88	3.5	55
3	Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. *Molecular Therapy*, **2004**, 10, 768-79	11.7	68
2	Lentivirally transduced dendritic cells as a tool for cancer immunotherapy. *Journal of Gene Medicine* , **2003**, 5, 654-67	3.5	145
1	Generation of large numbers of dendritic cells in a closed system using Cell Factories. *Journal of Immunological Methods*, **2002**, 264, 135-51	2.5	102